Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Lenvatinib After Definitive Chemoradiation in Locally Advanced HNSCC (PD-L1 CPS ≥1)
2024-516536-10-00Phase 2Authorised
- Sponsor
- Saarland University
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Saarland University. Primary endpoint: Event-free survival rate at 2 years. Planned start Sep 2024; status: authorised.
02
Drugs
pembrolizumablenvatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-516536-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516536-10-00.